JP2008507961A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008507961A5 JP2008507961A5 JP2007522989A JP2007522989A JP2008507961A5 JP 2008507961 A5 JP2008507961 A5 JP 2008507961A5 JP 2007522989 A JP2007522989 A JP 2007522989A JP 2007522989 A JP2007522989 A JP 2007522989A JP 2008507961 A5 JP2008507961 A5 JP 2008507961A5
- Authority
- JP
- Japan
- Prior art keywords
- cell
- cells
- tumor
- peripheral blood
- necrosis factor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP04017907.9 | 2004-07-29 | ||
| EP04017907A EP1621550A1 (en) | 2004-07-29 | 2004-07-29 | Tumor-homing cells engineered to produce tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) |
| PCT/EP2005/007957 WO2006010558A1 (en) | 2004-07-29 | 2005-07-21 | Tumor-homing cells engineered to produce tumor necrosis factor-related apoptosis-inducing ligand (trail) |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2008507961A JP2008507961A (ja) | 2008-03-21 |
| JP2008507961A5 true JP2008507961A5 (OSRAM) | 2008-09-11 |
| JP5042826B2 JP5042826B2 (ja) | 2012-10-03 |
Family
ID=34925971
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007522989A Expired - Fee Related JP5042826B2 (ja) | 2004-07-29 | 2005-07-21 | 腫瘍壊死因子関連アポトーシス誘導リガンド（ｔｒａｉｌ）を産生するように遺伝子操作された腫瘍帰巣細胞 |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US20070264231A1 (OSRAM) |
| EP (2) | EP1621550A1 (OSRAM) |
| JP (1) | JP5042826B2 (OSRAM) |
| KR (1) | KR20070047757A (OSRAM) |
| CN (1) | CN101076540B (OSRAM) |
| AT (1) | ATE455847T1 (OSRAM) |
| AU (1) | AU2005266543B2 (OSRAM) |
| BR (1) | BRPI0513855A (OSRAM) |
| CA (1) | CA2571426A1 (OSRAM) |
| DE (1) | DE602005019050D1 (OSRAM) |
| DK (1) | DK1771468T3 (OSRAM) |
| ES (1) | ES2340400T3 (OSRAM) |
| HR (1) | HRP20100227T1 (OSRAM) |
| IL (1) | IL180233A (OSRAM) |
| MX (1) | MX2007001152A (OSRAM) |
| NO (1) | NO20070956L (OSRAM) |
| NZ (1) | NZ552223A (OSRAM) |
| PL (1) | PL1771468T3 (OSRAM) |
| PT (1) | PT1771468E (OSRAM) |
| RS (1) | RS51381B (OSRAM) |
| RU (1) | RU2390558C2 (OSRAM) |
| SI (1) | SI1771468T1 (OSRAM) |
| WO (1) | WO2006010558A1 (OSRAM) |
| ZA (1) | ZA200701231B (OSRAM) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2008503468A (ja) * | 2004-06-18 | 2008-02-07 | ジェネンテック・インコーポレーテッド | Ａｐｏ２ｌレセプターアゴニストおよびｎｋ細胞活性化因子の使用方法 |
| DE102006020307A1 (de) * | 2006-05-03 | 2007-11-08 | Martin-Luther-Universität Halle-Wittenberg | TNF-related apoptosis-including (TRAIL)stabil transgen exprimierende mesenchymale Stammzellen, Verfahren zu ihrer Herstellung und zu ihrer Verwendung |
| WO2008142862A1 (ja) * | 2007-05-18 | 2008-11-27 | National University Corporation Asahikawa Medical College | 血管内皮前駆細胞の移植による抗がん療法 |
| CN102154213B (zh) * | 2011-01-19 | 2012-07-25 | 郑骏年 | 一种运载荷载细胞因子的双调控溶瘤腺病毒的新型cik细胞 |
| CN104160027B (zh) * | 2012-02-01 | 2016-06-22 | 浦项工科大学校产学协力团 | 同时表达十二聚体trail及hsv-tk自杀基因的载体及利用其的抗癌干细胞治疗剂 |
| CN103288966B (zh) * | 2013-05-17 | 2015-01-21 | 华侨大学 | 一种融合受体及其用于治疗大肠癌的基因药物 |
| RU2552609C1 (ru) * | 2013-10-28 | 2015-06-10 | Федеральное государственное бюджетное учреждение науки Институт молекулярной биотехнологии им. В.А. Энгельгардта Российской академии наук (ИМБ РАН) | Способ получения системы направленной доставки белковых молекул (онколитических белков) в опухолевые ткани на основе активированных лимфоцитов |
| WO2016065330A1 (en) | 2014-10-24 | 2016-04-28 | Aladar Szalay | Combination immunotherapy approach for treatment of cancer |
| CN116064401A (zh) * | 2015-07-29 | 2023-05-05 | 昂克医疗有限公司 | 具有增强的细胞毒性的修饰的天然杀伤细胞和天然杀伤细胞系 |
| US10906951B2 (en) * | 2015-07-29 | 2021-02-02 | Onk Therapeutics Limited | Modified natural killer cells and natural killer cell lines having increased cytotoxicity |
| WO2019232631A1 (en) * | 2018-06-06 | 2019-12-12 | Stemcell Technologies Canada Inc. | Kits, compositions and methods for myeloid-derived suppressor cell enrichment |
| US12220465B2 (en) | 2018-11-28 | 2025-02-11 | Washington University | Compositions and methods for targeted treatment and imaging of cancer or tumors |
| EP3712257A1 (en) | 2019-03-21 | 2020-09-23 | ONK Therapeutics Limited | Modified natural killer cells with increased resistance to cell death |
| CN113677791B (zh) * | 2019-03-21 | 2024-12-03 | 昂克医疗有限公司 | 对细胞死亡具有增加的抗性的经修饰的免疫效应细胞 |
| WO2021209625A1 (en) | 2020-04-17 | 2021-10-21 | Onk Therapeutics Limited | High potency natural killer cells |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5879672A (en) * | 1994-10-07 | 1999-03-09 | Regeneron Pharmaceuticals, Inc. | Tie-2 ligand 1 |
| AU747602B2 (en) * | 1997-06-04 | 2002-05-16 | Oxford Biomedica (Uk) Limited | Vector |
| WO2002022175A2 (en) * | 2000-09-11 | 2002-03-21 | Musc Foundation For Research Development | Method and composition for treating tumors by selective induction of apoptosis |
| EP1427813A2 (en) * | 2000-10-24 | 2004-06-16 | Immunex Corporation | Method for dendritic cells-based immunotherapy of tumors using combination therapy |
| US7235358B2 (en) * | 2001-06-08 | 2007-06-26 | Expression Diagnostics, Inc. | Methods and compositions for diagnosing and monitoring transplant rejection |
| JP4493882B2 (ja) * | 2001-06-19 | 2010-06-30 | 株式会社カネカ | 抗原およびこの抗原を識別するモノクローナル抗体 |
-
2004
- 2004-07-29 EP EP04017907A patent/EP1621550A1/en not_active Withdrawn
-
2005
- 2005-07-21 KR KR1020077000005A patent/KR20070047757A/ko not_active Ceased
- 2005-07-21 US US11/631,262 patent/US20070264231A1/en not_active Abandoned
- 2005-07-21 ES ES05764208T patent/ES2340400T3/es not_active Expired - Lifetime
- 2005-07-21 RU RU2007107369/13A patent/RU2390558C2/ru not_active IP Right Cessation
- 2005-07-21 HR HR20100227T patent/HRP20100227T1/hr unknown
- 2005-07-21 ZA ZA200701231A patent/ZA200701231B/xx unknown
- 2005-07-21 WO PCT/EP2005/007957 patent/WO2006010558A1/en not_active Ceased
- 2005-07-21 NZ NZ552223A patent/NZ552223A/en not_active IP Right Cessation
- 2005-07-21 MX MX2007001152A patent/MX2007001152A/es active IP Right Grant
- 2005-07-21 DK DK05764208.4T patent/DK1771468T3/da active
- 2005-07-21 PL PL05764208T patent/PL1771468T3/pl unknown
- 2005-07-21 BR BRPI0513855-8A patent/BRPI0513855A/pt not_active IP Right Cessation
- 2005-07-21 CN CN2005800324298A patent/CN101076540B/zh not_active Expired - Fee Related
- 2005-07-21 RS RSP-2010/0179A patent/RS51381B/sr unknown
- 2005-07-21 JP JP2007522989A patent/JP5042826B2/ja not_active Expired - Fee Related
- 2005-07-21 SI SI200530969T patent/SI1771468T1/sl unknown
- 2005-07-21 CA CA002571426A patent/CA2571426A1/en not_active Abandoned
- 2005-07-21 AT AT05764208T patent/ATE455847T1/de active
- 2005-07-21 EP EP05764208A patent/EP1771468B1/en not_active Expired - Lifetime
- 2005-07-21 AU AU2005266543A patent/AU2005266543B2/en not_active Ceased
- 2005-07-21 DE DE602005019050T patent/DE602005019050D1/de not_active Expired - Lifetime
- 2005-07-21 PT PT05764208T patent/PT1771468E/pt unknown
-
2006
- 2006-12-21 IL IL180233A patent/IL180233A/en not_active IP Right Cessation
-
2007
- 2007-02-20 NO NO20070956A patent/NO20070956L/no not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Ben Khelil et al. | Harnessing antitumor CD4+ T cells for cancer immunotherapy | |
| Zhang et al. | Interplay between inflammatory tumor microenvironment and cancer stem cells | |
| Elgert et al. | Tumor‐induced immune dysfunction: the macrophage connection | |
| Ringdén et al. | The allogeneic graft‐versus‐cancer effect | |
| Ni et al. | Sustained effector function of IL-12/15/18–preactivated NK cells against established tumors | |
| Körbling et al. | Twenty-five years of peripheral blood stem cell transplantation | |
| Zhang et al. | Neutrophils in cancer development and progression: roles, mechanisms, and implications | |
| Rezalotfi et al. | Gastric cancer stem cells effect on Th17/Treg balance; a bench to beside perspective | |
| JP2010501159A5 (OSRAM) | ||
| Medina-Echeverz et al. | Hepatic myeloid-derived suppressor cells in cancer | |
| Poyia et al. | The role of tumor microenvironment in pancreatic cancer immunotherapy: current status and future perspectives | |
| RU2007107369A (ru) | Мигрирующие в опухоль клетки, сконструированные с помощью опосредованного аденовирусом переноса гена, для получения лиганда (trail), индуцирующего апоптоз с участием фактора некроза опухоли | |
| Nguyen et al. | The role of Eph/ephrin molecules in stromal–hematopoietic interactions | |
| Li et al. | Adoptive cell immunotherapy for breast cancer: harnessing the power of immune cells | |
| Wang et al. | Mesenchymal stem cells in acquired aplastic anemia: The spectrum from basic to clinical utility | |
| Cui et al. | MDSCs: the key players in the formation of pre-metastatic niche | |
| JP2018522880A5 (OSRAM) | ||
| WO2018053618A1 (en) | Methods of culturing mesenchymal stromal cells | |
| JP2022513164A5 (OSRAM) | ||
| Gao et al. | Mining the multifunction of mucosal-associated invariant T cells in hematological Malignancies and transplantation immunity: A promising hexagon soldier in immunomodulatory | |
| Grisendi et al. | Tumor stroma manipulation by MSC | |
| Mossahebi-Mohammadi et al. | Efficient expansion of SALL4–transduced umbilical cord blood derived CD133+ hematopoietic stem cells | |
| A. Patel et al. | Stem cell transplantation for hematological malignancies: prospects for personalized medicine and co-therapy with mesenchymal stem cells | |
| Pakola et al. | Oncolytic adenovirus encoding variant interleukin-2 combined with chemotherapy enables PD-L1 inhibition in pancreatic cancer models | |
| CN110628717B (zh) | 一种浸润性t细胞的培养方法 |